All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2020-06-29T14:41:17.000Z

What are the key biological and clinical characteristics of patients with ultra-low-risk MM?

Bookmark this article

During the 25th Congress of the European Hematology Association (EHA), the MM Hub spoke to Mehmet Samur, Dana-Farber Cancer Institute, Boston, US. We asked, What are the key biological and clinical characteristics of patients with ultra-low-risk MM?

What are the key biological and clinical characteristics of patients with ultra-low-risk MM?

Until now, the primary focus of genomic studies in the MM setting has been high-risk disease. Here, Mehmet Samur discusses a study in which patients with newly diagnosed MM underwent whole genome sequencing with the aim to define low-risk patients.

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox